中国·腾博-www.tengbo9885.com|官网首发

中文
中文

以患者需求为核心,驱动细胞免疫治疗创新,实现癌症可控化并最终治愈。

We strive to make patients-driven cellular immunotherapy innovation, to transform cancer into a manageable condition — and ultimately cure it.

2022
  • 0
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. 
Cancer Cell 40, 674-693, June 13, 2022    doi:https://doi.org/10.1016/j.ccell.2022.04.018

Haixia Long, Qingzhu Jia, Liuyang Wang, Wenfeng Fang, Zhongyu Wang, Tao Jiang, Fei Zhou, Zheng Jin, Jiani Huang, Li Zhou, Chunyan Hu, Xinxin Wang, Jin Zhang, Yujie Ba, Yujie Gong, Xianghua Zeng, Dong Zeng, Xingxing Su, Peter B. Alexander, Li Wang, Limei Wang, Yisong Y. Wan, Xiao-Fan Wang, Li Zhang, Qi-Jing Li, Bo Zhu ( 2022)   

Breaking boundaries: current progress of anticancer NK cell-based drug development
Drug Discovery Today, PII: S1359-6446(22)00429-9 doi: https://doi.org/10.1016/j.drudis.2022.103436
Reference: DRUDIS 103436
Shuhang Wang, Kun Chen, Yale Jiang, Guo Zhao, Caie Wang, Hong Fang, Qiyu Tang, Chao Sun, Liang Zhang, Haiyang Wu, Li-Feng Zhang, Ning Li 

 
  • 上一篇:--
  • 下一篇:2021
06.14
2022
来源:
关键词:
相关阅读
关于腾博tengbo9885官网
研究与发展
产品及临床
新闻与媒体
XML 地图